. 2008 Sep;6(Suppl 2):s33–s38. doi: 10.2450/2008.0035-08

Table I.

Literature results on short-term prophylaxis in von Willebrand’s disease.

Author, year^reference	Product	Cases	VWD types	Type of intervention	Dose range	Efficacy (%)
*Desmopressin*
Federici, 2000⁴	DDAVP	27	20 type 1, 7 type 2	27 oral surgery	0.3 μg/kg IV	100
Leissinger, 2001⁵	DDAVP	37	37 type 1	37 oral or surgical procedures	1.5 mg/mL IN	93
Nitu-Whalley, 2001⁶	DDAVP	35	25 type 1, 2 type M	3 major, 13 minor, 19 oral surgery	0.3 μg/kg IV	91
*VWF/FVIII concentrates*
Goudemand, 1998⁷	VHP	54	NI	23 major, 31 minor surgery	51–55 IU VWF:RCo/kg	100
Federici, 2002⁸	Fanhdi	14	5 type 1, 7 type 2, 2 type 3	7 major, 5 minor, 2 oral surgery	17–92 IU FVIII:C/kg/d	93
Mannucci, 2002⁹	Alphanate	71	6 type 1, 19 type 2, 14 type 3	71 surgical or invasive procedures	20–76 IU VWF:RCo/kg	96
Lillicrap, 2002¹⁰	Haemate P	73	26 type 1, 20 type 2, 21 type 3, 6 NI	73 surgery	11.9–222.8 IU VWF:RCo/kg	99
Franchini, 2003¹¹	Haemate P	43	19 type 1, 7 type 2	14 major, 11 minor, 11 oral surgery, 7 IP	21.4–52.5 IU VWF:RCo/kg/d	98
Thompson, 2004¹²	Haemate P	42	16 type 1, 9 type 2, 8 type 3, 6 NI	25 major, 17 minor surgery	32.5–216.8 IU VWF:RCo/kg	100
Bernstein, 2006¹³	Haemate P	35	17 type 1, 12 type 2, 13 type 3	25 major, 7 minor, 3 oral surgery	17.4–135.3 IU VWF:RCo/kg	91
Federici, 2007¹⁴	Haemate P	73	19 type 1, 27 type 2, 10 type 3	17 major, 28 minor, 19 oral surgery, 9 IP	27–146 IU VWF:RCo/kg/d	97
Lethagen, 2007¹⁵	Haemate P	29	10 type 1, 11 type 2, 8 type 3	16 major, 11 minor	50.1–87.0 IU VWF:RCo/kg	96
Borel-Derlon, 2007¹⁶	Wilfactin	108	5 type 1, 25 type 2, 14 type 3	43 major or minor, 14 oral surgery, 51 IP	11.1–100 IU VWF:RCo/kg	100

Abbreviations: DDAVP, desmopressin; VWD, von Willebrand’s disease; VWF, von Willebrand factor; FVIII:C, factor VIII coagulant activity; IV, intravenously; IN, intranasal; NI, not indicated; VWF:RCo, von Willebrand factor ristocetin cofactor; IP, invasive procedures; d, day.